

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

Capitol Annex -Room 131

700 Capital Avenue Frankfort, Kentucky 40601

Thursday, September 19, 2019

1:00 P.M. to 4:00 P.M.

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
 - a. Approval of Meeting Minutes
- IV. New Business**
 - a. New Products to Market to be reviewed as single products:
 - i. Evenity™ (Bone Resorption Suppression and Related Agents)
 - ii. Skyrizi™ (Cytokines and CAM Antagonists)
 - iii. Mavenclad® (Multiple Sclerosis Agents)
 - iv. Mayzent® (Multiple Sclerosis Agents)
 - v. Piqray® (Oncology, Oral – Breast)
 - vi. Balversa™ (Oncology, Oral – Other)
 - b. New Products to Market to be reviewed along with their respective classes:
 - i. Bevyxxa™ (Anticoagulants)
 - ii. Diacomit™ (Anticonvulsants)
 - iii. Spravato™ (Antidepressants, Other)
- V. Clinical Criteria Review (to occur within their respective class reviews)**
 - a. Angiotensin Modulator Combination Step Therapy Requirements
 - b. Emgality™ for Episodic Cluster Headache
- VI. Therapeutic Classes with Recommended Changes**
 - a. Angiotensin Modulator Combinations
 - b. Antiarrhythmics, Oral
 - c. Anticoagulants (includes new agent Bevyxxa™)
 - d. Anticonvulsants
 - i. Anticonvulsants: Carbamazepine Derivatives
 - ii. Anticonvulsants: First Generation
 - iii. Anticonvulsants: Second Generation (includes new agent Diacomit™)
 - e. Antidepressants, Other
 - i. Antidepressants: MAOIs
 - ii. Antidepressants: Other (includes new agent Spravato™)
 - iii. Antidepressants: SNRIs
 - f. Antimigraine Agents, Other (Anti-Migraine Agents: CGRP Inhibitors)
 - g. Antiparkinson's Agents (Parkinson's Disease)

- h. Antipsychotics
 - i. First-Generation Antipsychotics
 - ii. Second-Generation Antipsychotics
 - iii. Antipsychotics: Injectable
 - iv. Atypical Antipsychotic and SSRI Combinations
- i. Anxiolytics
- j. Calcium Channel Blockers
 - i. Calcium Channel Blockers (DHP)
 - ii. Calcium Channel Blockers (Non-DHP)
- k. Neuropathic Pain
- l. Stimulants and Related Agents
 - i. Narcolepsy Agents
 - ii. Stimulants and Related Agents

VII. Consent Agenda

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

Alzheimer's Agents	Lipotropics, Other
Angiotensin Modulators	Lipotropics, Statins
Antianginal & Anti-Ischemic	Movement Disorders
Antidepressants, SSRIs	PAH Agents, Oral and Inhaled
Antidepressants, Tricyclic	Platelet Aggregation Inhibitors
Antimigraine Agents, Triptans	Sedative Hypnotics
Beta-Blockers	Skeletal Muscle Relaxants
Bladder Relaxant Preparations	Smoking Cessation
BPH Treatments	

VIII. Adjournment

- a. Schedule of Upcoming Meetings
 - i. **November 21, 2019**
- b. Collection of Travel Vouchers

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.